Evaluation of Serum Serotonin as a Biomarker for Myocardial Infarction and Ischemia/Reperfusion Injury

Evaluation of Serum Serotonin as a Biomarker for Myocardial Infarction and Ischemia/Reperfusion Injury

Blog Article

Background: Activated platelets release serotonin during acute myocardial infarction (AMI), aggravating iphone 13 pro max price florida myocardial damage and ischemia/reperfusion (I/R) injury.However, serum serotonin and its potential role as a biomarker for myocardial infarction and I/R injury have not been studied so far.Methods: In this investigator-initiated pilot study, we examined 38 patients with ST-segment myocardial infarction (STEMI).

We determined serum serotonin levels prior to percutaneous coronary intervention and 8, 16, and 24 h afterwards.We studied whether serum serotonin was associated with I/R injury assessed by ECG analysis and by analysis of TIMI myocardial perfusion grade (TMP) and myocardial blush grade (MGB).Serum serotonin levels were compared to an age-matched control group consisting of patients admitted to the emergency department for any other reason than STEMI.

Results: Serum serotonin levels were not elevated in the myocardial infarction group compared to the control cohort and they did not show any timeline kinetics sequal eclipse 5 battery after STEMI.They were not associated with the severity of coronary artery disease, the outcome of coronary angiography, the extent of I/R injury, or the degree of heart failure.Conclusions: Serum serotonin is not suitable as a biomarker after myocardial infarction and in the assessment of I/R injury.